ClinicalTrials.gg
DrugBiological

Poly ICLC clinical trials

Also written Hiltonol and NSC-301463.

studies test it
61
open now
3
in phase 3
0
first study started
2002

How each study uses poly ICLC is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the poly ICLC studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Poly ICLC
22
Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose
7
Stabilized Polyriboinosinic/Polyribocytidylic Acid
6
Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose
5
Poly I:Poly C with Poly-L-Lysine Stabilizer
4

Development codes

NSC-301463
2

Other names

Hiltonol
31
Poly-ICLC
22

In one entry with another drug

Given together, or one or the other

NeoVax
4
neoantigen vaccine
2

Studies by the year they started

61 studies that test it; most in 2014 (7)

Studies that test poly ICLC, by start year
YearStudies
20021
20031
20061
20072
20082
20096
20103
20114
20123
20131
20147
20154
20162
20172
20184
20194
20201
20213
20225
20233
20242

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
48
Phase 2
22
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 54

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Washington University School of Medicine (4) · Dana-Farber Cancer Institute (3) · Rockefeller University (3) · Patrick Ott, MD, PhD (2) · Roswell Park Cancer Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Nina Bhardwaj (2)

Often tested with

Tested in the same studies.

flt3 ligand protein (5) · NeoVax (4) · Rasdegafusp alfa (4) · CDX-301 (3) · Peptides (2) · IMA950 (2) · Protein Subunit Vaccines (2) · CDX-1140 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test poly ICLC.

Studies

Open first, then newest update. How each study uses poly ICLC is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 61

See all 61 studies that test poly ICLC →

Given beside what is tested · 30 — poly ICLC is usual care or a partner of the new treatment

Showing 20 of 30.

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call poly ICLC · ClinicalTrials.gg INT002713

  • MeSH (NLM) C019531poly ICLCConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7KYP9TKT70HILTONOLConfirmed FDA, NLM
  • NCI Thesaurus C1198Poly ICLCOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.